Helmholtz-zentrum Fuer Infektionsforschung Gmbh

Helmholtz-zentrum Fur Infektionsforschung Gmbh

Gesellschaft Fuer Biotechnologische Forschung Mbh (gbf)

Siegfried Weiss

Carlos A Guzman

Kenneth Nigel Timmis

Birgit Gerstel

Holger Loessner

Petra Wachholz

Ayub Darji

Sebastian Felgner

Trinad Chakraborty

Anne Endmann

Jürgen Wehland

Dino Kocijancic

Marc Erhardt

Sara Leschner

Holger Lössner

Kathrin Westphal

In a first aspect, the present invention relates to a mutatedstrain comprising mutations in flagellin II genes, like the fliF gene, in particular, in addition the aroA gene, the IpxR gene, the pagP gene, the pagL gene, the ydiV gene and optionally the eptA gene and further optionally, the arnT gene. In a further aspect, immunogenic compositions comprising saidstrain are provided optionally together with a pharmaceutically accepted carrier, diluent or effluent. Moreover, a method for producing outer membrane vesicles ofis provided, said method comprises the steps of cultivating thestrain according to the present invention and isolating the outer membrane vesicles accordingly. The present invention provides the bacteria or the outer membrane vesicles (OMVs) obtainable by the methods according to the present invention and its use as a transport moiety or as an immunogenic composition, like a vaccine or immunotherapy platform espedaily for therapeutic treatment of cancer of tissue or blood.

and immunogenic composition containing the same as well as its use

The present invention relates to a combination of compounds for introducing nucleic acids and/or protein into animal cells, tissue, organs or organisms in vitro, extracorporal, or in vivo. This combination comprises preparations suitable for administration to an animal or human for medical purposes, comprising as one component a bacterial vector genetically manipulated to contain nucleic acid sequences comprising a transgene, and a second component for the subsequent transcription, possibly translation of the transgene by controlled induction of bacterial vector as it is present within the animal or human.

Bacterial vector

The present invention is directed to an attenuatedcomprising a eukaryotic expression vector for delivery of the eukaryotic expression vector to a eukaryotic cell. Delivery may be to eukaryotic cells cultured in vitro or to cells in vivo, such as by oral administration of the attenuatedcomprising the eukaryotic expression vector.

[object Object]

Growing community of inventors

Braunschweig, Germany

Siegfried Weiss